Amgen is among the global top 10 pharmaceutical companies based on market value. As of August 2018, the company was worth some 128 billion U.S. dollars. Biopharmaceuticals manufactured by Amgen are also among the leading biotech drugs worldwide. Enbrel and Neulasta are the company’s flagship products, responsible for nearly half of Amgen’s total revenue. Interestingly, Amgen generates almost 80 percent of its revenues on the domestic U.S. market.
As is common in the biopharmaceutical industry, Amgen spends a significant proportion of its income on research and development. In 2018, Amgen spent nearly 16 percent of its revenue on R&D purposes. Some 28 percent of 3.74 billion dollars of R&D spending was for late-stage clinical programs, while the rest was for discovery research and for marketed products.